Lonza
Basel · Founded 1897
About Lonza
Lonza Group AG, a Life Sciences driven chemical company, supplies active ingredients, chemical intermediates and biotechnology solutions to the pharmaceutical and agrochemical industries. The company also offers a catalogue of organic intermediates for a range of applications, such as pharmaceuticals, agrochemicals, vitamins, food and feedstuff, dyes and pigments, adhesives and fragrances. It also manufactures specialty biocides and oleochemicals; and develops and produces specific polymer intermediates, unsaturated polyester-resins, compounds and composites. The company operates in three divisions that include Exclusive Synthesis & Biopharmaceuticals; Organic Fine & Performance Chemicals; and Polymer Intermediates. Exclusive Synthesis & Biopharmaceuticals In the area of Exclusive Synthesis and Biopharmaceuticals, Lonza is the custom manufacturing for the global life sciences companies. In addition to Lonza's traditional chemical custom manufacturing, Lonza offers microbial custom fermentation and biotransformation services. Lonza Biologics is focused on the production of therapeutic monoclonal antibodies and recombinant proteins produced by mammalian cell cultures. Exclusive chemical synthesis: Exclusive chemical synthesis engages in the process development and manufacture of intermediates and active ingredients. It is used in Life sciences industry, pharmaceuticals and animal health products. Exclusive microbial fermentation and biotransformation: Exclusive microbial fermentation and biotransformation processes development and manufactures intermediates, active ingredients and biopharmaceuticals. Its products are used Life sciences industry, pharmaceuticals and cosmetics. The company also offers L-Carnitine (L-Carnipure), which is applicable in sports nutrition, food, pharmaceuticals and feedstuffs. Exclusive microbial biopharma fermentation: Exclusive microbial biopharma fermentation engages in the process development and manufacture of therapeutic recombinant proteins and antibody fragments. It is used in pharmaceutical and biotechnology industry. Exclusive mammalian cell fermentation: Exclusive mammalian cell fermentation engages in the process development and manufacture of therapeutic monoclonal antibodies and recombinant proteins, proprietary GS-expression system, which are used in the pharmaceutical and biotechnology industry. Organic Fine & Performance Chemicals In the area of organic fine and performance chemicals, the company develops, manufactures, and sells various organic chemical intermediates applied in pharmaceuticals, agrochemicals, vitamins, food and feed, dyes, pigments, adhesives, and fragrances, as well as polymers. The sector performance chemical is mainly engaged in the development and production of biocides and oleochemicals. These core activities are supplemented by the polymer intermediates business, including additives, unsaturated polyester resins, compounds, and composites. Organic Fine Chemicals: The company offers Niacin, niacinamide, Diketene derivatives, Hydrocyanic acid derivatives, Engineering polymer additives and Meta ’ Metaldehyde. Its products are used in food and feedstuffs, pharmaceuticals, agrochemicals, colorants Vitamins, optical brighteners, agrochemicals, electronics, aerospace industry, and coating Snail. Performance Chemicals: The company offers microbiologically active substances, such as Quaternary ammonium, compounds, Halogenated hydantoins; and Hydantoin derivatives. It also offers Oleochemical derivatives. The company's products are used by the disinfectants for household, industrial and institutional applications, including water treatment and wood preservation; biocides for water treatment, pools and spas, and household disinfection; preservatives for personal care and household products; and food ingredients, humectants and emollients for personal care, processing aids and lubricants for polymer and textile industry, and industrial defoamers.
Company Facts
- Founded: 1897
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 10,001+
- Estimated revenue: $1M – $10M
- Total funding: $444.8M
- Funding stage: IPO
- Last round: Post-IPO Debt (Nov 2023)
- Ticker: swx:LONN
- Website: lonza.com
- Phone: 00041 61 316 81 11
Industries & Categories
Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/lonza-19219 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.